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In cell-based influenza vaccine production, the European Pharmacopoeia demands a host cell residual DNA 
concentration of less than 10 ng per dose. To reliably measure residual DNA in both process samples and final 
vaccine using quantitative PCR, DNA preparation prior to analysis is a necessity.  Samples from the vaccine 
purification process contain different buffers, salts, and cell-based compounds, and vary 3–4 logs in DNA 
concentration from harvest to the final product, which all put strain on the DNA preparation. For accurate 
determination of DNA concentration, recovery is of high importance. There are many commercially available 
DNA preparation kits that use different techniques to bind DNA, from spin columns with a DNA-binding 
membrane or medium (resin) to magnetic beads. However, these kits are mainly developed to purify DNA 
fragments from gel electrophoresis or genomic DNA from tissues such as blood or cultured cells, and do not 
have recovery as a priority. Few kits are intended for residual DNA determination in samples with high 
concentration of a protein or virus product. In this study, prototype media for DNA preparation, in bind-elute and 
batch mode, were evaluated for recovery, hands-on time, and throughput. In batch mode, recoveries of > 80% 
were achieved, but the technique exhibited matrix effects on real process samples. In bind-elute mode, 
recoveries of 40%–60% were achieved after elution. However, recovery could be improved by determination of 
DNA concentration, while keeping DNA bound to the medium. 
 
